HMGCR and neoplasm: A precedent has already been set in melanoma-bearing mice; combined implementation of the OXPHOS inhibitor IACS-010759, and Atorvastatin, a hydroxymethylglutaryl-CoA reductase (HMGCR) and cholesterol synthesis inhibitor, completely abrogated tumour growth [232].